MEDISTIM ASA (MEDI.OL) Fundamental Analysis & Valuation

OSL:MEDI • NO0010159684

216 NOK
-6 (-2.7%)
Last: Mar 6, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This MEDI.OL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

7

Overall MEDI gets a fundamental rating of 7 out of 10. We evaluated MEDI against 63 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making MEDI a very profitable company, without any liquidiy or solvency issues. MEDI is valued quite expensive, but it does show an excellent growth. These ratings could make MEDI a good candidate for growth and quality investing.


Dividend Valuation Growth Profitability Health

9

1. MEDI.OL Profitability Analysis

1.1 Basic Checks

  • MEDI had positive earnings in the past year.
  • MEDI had a positive operating cash flow in the past year.
  • Each year in the past 5 years MEDI has been profitable.
  • MEDI had a positive operating cash flow in each of the past 5 years.
MEDI.OL Yearly Net Income VS EBIT VS OCF VS FCFMEDI.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

1.2 Ratios

  • With an excellent Return On Assets value of 24.76%, MEDI belongs to the best of the industry, outperforming 98.41% of the companies in the same industry.
  • MEDI's Return On Equity of 34.02% is amongst the best of the industry. MEDI outperforms 98.41% of its industry peers.
  • With an excellent Return On Invested Capital value of 30.97%, MEDI belongs to the best of the industry, outperforming 98.41% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for MEDI is significantly above the industry average of 9.88%.
  • The 3 year average ROIC (24.89%) for MEDI is below the current ROIC(30.97%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 24.76%
ROE 34.02%
ROIC 30.97%
ROA(3y)20.73%
ROA(5y)20.96%
ROE(3y)26.96%
ROE(5y)27.52%
ROIC(3y)24.89%
ROIC(5y)25.57%
MEDI.OL Yearly ROA, ROE, ROICMEDI.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30

1.3 Margins

  • The Profit Margin of MEDI (21.30%) is better than 90.48% of its industry peers.
  • In the last couple of years the Profit Margin of MEDI has remained more or less at the same level.
  • MEDI has a Operating Margin of 26.88%. This is amongst the best in the industry. MEDI outperforms 93.65% of its industry peers.
  • In the last couple of years the Operating Margin of MEDI has remained more or less at the same level.
  • With an excellent Gross Margin value of 81.21%, MEDI belongs to the best of the industry, outperforming 93.65% of the companies in the same industry.
  • In the last couple of years the Gross Margin of MEDI has remained more or less at the same level.
Industry RankSector Rank
OM 26.88%
PM (TTM) 21.3%
GM 81.21%
OM growth 3Y-5.05%
OM growth 5Y-1.15%
PM growth 3Y-4.63%
PM growth 5Y-0.92%
GM growth 3Y1.08%
GM growth 5Y0.46%
MEDI.OL Yearly Profit, Operating, Gross MarginsMEDI.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. MEDI.OL Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), MEDI is creating value.
  • MEDI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MEDI.OL Yearly Shares OutstandingMEDI.OL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
MEDI.OL Yearly Total Debt VS Total AssetsMEDI.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • MEDI has a debt to FCF ratio of 0.11. This is a very positive value and a sign of high solvency as it would only need 0.11 years to pay back of all of its debts.
  • MEDI has a Debt to FCF ratio of 0.11. This is amongst the best in the industry. MEDI outperforms 96.83% of its industry peers.
  • A Debt/Equity ratio of 0.05 indicates that MEDI is not too dependend on debt financing.
  • MEDI has a Debt to Equity ratio of 0.05. This is amongst the best in the industry. MEDI outperforms 88.89% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF 0.11
Altman-Z N/A
ROIC/WACC3.63
WACC8.54%
MEDI.OL Yearly LT Debt VS Equity VS FCFMEDI.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 3.33 indicates that MEDI has no problem at all paying its short term obligations.
  • The Current ratio of MEDI (3.33) is better than 88.89% of its industry peers.
  • A Quick Ratio of 2.03 indicates that MEDI has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 2.03, MEDI belongs to the best of the industry, outperforming 82.54% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.33
Quick Ratio 2.03
MEDI.OL Yearly Current Assets VS Current LiabilitesMEDI.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. MEDI.OL Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 40.36% over the past year.
  • Measured over the past 5 years, MEDI shows a small growth in Earnings Per Share. The EPS has been growing by 7.96% on average per year.
  • Looking at the last year, MEDI shows a very strong growth in Revenue. The Revenue has grown by 22.21%.
  • The Revenue has been growing by 9.12% on average over the past years. This is quite good.
EPS 1Y (TTM)40.36%
EPS 3Y4.41%
EPS 5Y7.96%
EPS Q2Q%48.5%
Revenue 1Y (TTM)22.21%
Revenue growth 3Y9.6%
Revenue growth 5Y9.12%
Sales Q2Q%25.68%

3.2 Future

  • MEDI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.78% yearly.
  • The Revenue is expected to grow by 11.00% on average over the next years. This is quite good.
EPS Next Y16.97%
EPS Next 2Y13.46%
EPS Next 3Y11.78%
EPS Next 5YN/A
Revenue Next Year17.55%
Revenue Next 2Y12.56%
Revenue Next 3Y11%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MEDI.OL Yearly Revenue VS EstimatesMEDI.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 200M 400M 600M 800M
MEDI.OL Yearly EPS VS EstimatesMEDI.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

3

4. MEDI.OL Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 27.73, the valuation of MEDI can be described as expensive.
  • MEDI's Price/Earnings is on the same level as the industry average.
  • When comparing the Price/Earnings ratio of MEDI to the average of the S&P500 Index (26.29), we can say MEDI is valued inline with the index average.
  • With a Price/Forward Earnings ratio of 27.65, MEDI can be considered very expensive at the moment.
  • Based on the Price/Forward Earnings ratio, MEDI is valued a bit more expensive than the industry average as 65.08% of the companies are valued more cheaply.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.57, MEDI is valued at the same level.
Industry RankSector Rank
PE 27.73
Fwd PE 27.65
MEDI.OL Price Earnings VS Forward Price EarningsMEDI.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MEDI is on the same level as its industry peers.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of MEDI indicates a somewhat cheap valuation: MEDI is cheaper than 74.60% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 20.74
EV/EBITDA 19.27
MEDI.OL Per share dataMEDI.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • MEDI's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • MEDI has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)1.63
PEG (5Y)3.48
EPS Next 2Y13.46%
EPS Next 3Y11.78%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. MEDI.OL Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 3.60%, MEDI has a reasonable but not impressive dividend return.
  • Compared to an average industry Dividend Yield of 1.11, MEDI pays a better dividend. On top of this MEDI pays more dividend than 90.48% of the companies listed in the same industry.
  • MEDI's Dividend Yield is rather good when compared to the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 3.6%

5.2 History

  • The dividend of MEDI is nicely growing with an annual growth rate of 14.87%!
Dividend Growth(5Y)14.87%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • The dividend of MEDI is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DPN/A
EPS Next 2Y13.46%
EPS Next 3Y11.78%
MEDI.OL Yearly Income VS Free CF VS DividendMEDI.OL Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

Find the best dividend stocksShow peers with best dividend

MEDI.OL Fundamentals: All Metrics, Ratios and Statistics

MEDISTIM ASA

OSL:MEDI (3/6/2026, 7:00:00 PM)

216

-6 (-2.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-27
Earnings (Next)05-07
Inst Owners60.88%
Inst Owner ChangeN/A
Ins Owners0.07%
Ins Owner ChangeN/A
Market Cap3.96B
Revenue(TTM)668.61M
Net Income(TTM)142.42M
Analysts85.71
Price Target260.1 (20.42%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.6%
Yearly Dividend4.5
Dividend Growth(5Y)14.87%
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.92%
PT rev (3m)-1.92%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 27.73
Fwd PE 27.65
P/S 5.92
P/FCF 20.74
P/OCF 20.74
P/B 9.46
P/tB 11.4
EV/EBITDA 19.27
EPS(TTM)7.79
EY3.61%
EPS(NY)7.81
Fwd EY3.62%
FCF(TTM)10.42
FCFY4.82%
OCF(TTM)10.42
OCFY4.82%
SpS36.46
BVpS22.82
TBVpS18.94
PEG (NY)1.63
PEG (5Y)3.48
Graham Number63.25
Profitability
Industry RankSector Rank
ROA 24.76%
ROE 34.02%
ROCE 40.19%
ROIC 30.97%
ROICexc 47.84%
ROICexgc 63.44%
OM 26.88%
PM (TTM) 21.3%
GM 81.21%
FCFM 28.57%
ROA(3y)20.73%
ROA(5y)20.96%
ROE(3y)26.96%
ROE(5y)27.52%
ROIC(3y)24.89%
ROIC(5y)25.57%
ROICexc(3y)39.99%
ROICexc(5y)39.99%
ROICexgc(3y)48.52%
ROICexgc(5y)48.01%
ROCE(3y)32.29%
ROCE(5y)33.19%
ROICexgc growth 3Y-6.52%
ROICexgc growth 5Y0.36%
ROICexc growth 3Y-8.47%
ROICexc growth 5Y0.04%
OM growth 3Y-5.05%
OM growth 5Y-1.15%
PM growth 3Y-4.63%
PM growth 5Y-0.92%
GM growth 3Y1.08%
GM growth 5Y0.46%
F-Score6
Asset Turnover1.16
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF 0.11
Debt/EBITDA 0.1
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion 93.53%
Profit Quality 134.12%
Current Ratio 3.33
Quick Ratio 2.03
Altman-Z N/A
F-Score6
WACC8.54%
ROIC/WACC3.63
Cap/Depr(3y)105.67%
Cap/Depr(5y)N/A
Cap/Sales(3y)4.78%
Cap/Sales(5y)N/A
Profit Quality(3y)91.83%
Profit Quality(5y)103.03%
High Growth Momentum
Growth
EPS 1Y (TTM)40.36%
EPS 3Y4.41%
EPS 5Y7.96%
EPS Q2Q%48.5%
EPS Next Y16.97%
EPS Next 2Y13.46%
EPS Next 3Y11.78%
EPS Next 5YN/A
Revenue 1Y (TTM)22.21%
Revenue growth 3Y9.6%
Revenue growth 5Y9.12%
Sales Q2Q%25.68%
Revenue Next Year17.55%
Revenue Next 2Y12.56%
Revenue Next 3Y11%
Revenue Next 5YN/A
EBIT growth 1Y40.96%
EBIT growth 3Y4.07%
EBIT growth 5Y7.86%
EBIT Next Year34.29%
EBIT Next 3Y15.73%
EBIT Next 5YN/A
FCF growth 1Y81.09%
FCF growth 3Y-0.65%
FCF growth 5Y12.16%
OCF growth 1Y81.09%
OCF growth 3Y3.75%
OCF growth 5Y12.23%

MEDISTIM ASA / MEDI.OL FAQ

What is the ChartMill fundamental rating of MEDISTIM ASA (MEDI.OL) stock?

ChartMill assigns a fundamental rating of 7 / 10 to MEDI.OL.


What is the valuation status for MEDI stock?

ChartMill assigns a valuation rating of 3 / 10 to MEDISTIM ASA (MEDI.OL). This can be considered as Overvalued.


How profitable is MEDISTIM ASA (MEDI.OL) stock?

MEDISTIM ASA (MEDI.OL) has a profitability rating of 9 / 10.


What are the PE and PB ratios of MEDISTIM ASA (MEDI.OL) stock?

The Price/Earnings (PE) ratio for MEDISTIM ASA (MEDI.OL) is 27.73 and the Price/Book (PB) ratio is 9.46.


What is the financial health of MEDISTIM ASA (MEDI.OL) stock?

The financial health rating of MEDISTIM ASA (MEDI.OL) is 7 / 10.